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Thromboembolic disease is a major cause of mortality and morbidity in the developed world
and is caused by an excessive stimulation of coagulation.Thrombin is a key serine protease
in the coagulation cascade and numerous efforts have been made to develop safe and effec-
tive orally active direct thrombin inhibitors (DTIs). Current anticoagulant therapy includes
the use of indirect thrombin inhibitors (e.g., heparins, low-molecular-weight-heparins) and
vitamin K antagonists such as warfarin. However there are several caveats in the clinical
use of these agents including narrow therapeutic window, parenteral delivery, and food-
and drug–drug interactions. Dabigatran is a synthetic, reversible DTI with high affinity and
specificity for its target binding both free and clot-bound thrombin, and offers a favorable
pharmacokinetic profile. Large randomized clinical trials have demonstrated that dabigatran
provides comparable or superior thromboprophylaxis in multiple thromboembolic disease
indications compared to standard of care. This minireview will highlight the discovery and
development of dabigatran, the first in a class of new oral anticoagulant agents to be
licensed worldwide for the prevention of thromboembolism in the setting of orthopedic
surgery and stroke prevent in atrial fibrillation.
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INTRODUCTION
Thrombin is a serine protease and is the main effector protease
in the blood coagulation cascade (Figure 1A), exhibiting both
pro- and anticoagulant properties (Griffin, 1995; Di Cera, 2008).
Thrombin (FIIa) is generated via proteolytic cleavage from inac-
tive prothrombin (FII) by factor Xa (FXa) in the prothrombinase
complex, which assembles when circulating coagulation factors
come into contact with tissue factor (TF) on exposed extravascular
tissues. Thrombin plays a central role in the initiation and prop-
agation of thrombotic disease by activating platelets, catalyzing
fibrinogen conversion into fibrin, and promoting clot stabiliza-
tion (Lane et al., 2005). Thrombin activates upstream factors in the
cascade to amplify the coagulation response and enhance throm-
bin generation. Its activity is inhibited via endogenous circulating
anticoagulants including antithrombin (AT), heparin cofactor II
(HCII), and binding to the cofactor thrombomodulin (TM) to
activate the anticoagulant protein C (Griffin,1995). Thrombin also
induces many cellular effects via a family of G-protein coupled pro-
tease activated receptors (PAR), PAR1, PAR3, and PAR4 (Coughlin,
2005; Figure 1B). The expression of PAR1 on the endothelium and
vasculature, in both physiological and disease states, suggests that
thrombin plays a role in these contexts.
Established anticoagulation therapy has targeted thrombin.
The parenteral agents heparin and low molecular weight heparins
(LMWH) catalyze the inhibition of thrombin by AT and are used
for prophylaxis and treatment of venous thromboembolism (VTE)
in many indications (Hirsh et al., 2008). Other approved parenteral
thrombin inhibitors include the recombinant hirudin lepirudin
and synthetic direct thrombin inhibitor (DTI) argatroban (Cop-
pens et al., 2012), for predominantly heparin-induced thrombo-
cytopenia (Yeh and Jang, 2006), and the oligopeptide bivalirudin
in percutaneous coronary interventions (Warkentin et al., 2008).
As the only available oral therapy, warfarin and its derivatives
have been used for over 50 years in long-term anticoagulation
treatment (Hirsh et al., 1998). Warfarin, a Vitamin K antagonist
(VKA), blocks the biosynthesis of thrombin and other coagulation
factors and has proven effective in inhibiting thrombosis. How-
ever, administration is problematic due to its slow onset-offset of
activity, and drug–drug and drug-food interactions which require
frequent monitoring and dose adjustment to maintain appropriate
anticoagulation (Mann, 2005).
Research activities in many pharmaceutical companies have
focused on the identification of novel thrombin inhibitors. In 2004
a new DTI ximelagatran (AstraZeneca; Gustafsson et al., 2004)
gained approval in several countries for short-term anticoagula-
tion treatment after orthopedic surgery, but was later withdrawn
due to hepatotoxicity reports. Other companies concentrated their
research activities on discovering FXa inhibitors (Pinto et al., 2010)
including two recently approved FXa inhibitors – rivaroxaban and
apixaban for treatment and prevention of VTE after orthopedic
surgery (Pinto et al., 2007; Perzborn et al., 2011) and stroke pre-
vention in atrial fibrillation (Granger et al., 2011; Patel et al., 2011).
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FIGURE 1 | (A) Simplified schematic of thrombin in the coagulation cascade. (B) Overview of thrombin’s non-hemostatic effects via PAR receptor signaling in
diverse cell types.
Two additional FXa inhibitors, edoxaban (Furugohri et al., 2008)
and betrixaban (Zhang et al., 2009), are completing Phase III trials.
This review will focus on the development of dabigatran (Hauel
et al., 2002), the first new oral anticoagulant (NOAC) to gain mar-
ket approval for long-term indications 50 years after introduction
of warfarin. Dabigatran is approved in over 70 countries, includ-
ing the U.S., Canada, Europe, and Japan, for stroke prevention in
patients with atrial fibrillation and for the prevention of thrombo-
sis after orthopedic hip and knee surgery. Dabigatran is a potent,
reversible, and direct inhibitor of thrombin, with a good efficacy,
safety, and tolerability profile as compared to both warfarin and
LMWH (Hankey and Eikelboom, 2011).
DABIGATRAN DISCOVERY AND PRECLINICAL
PHARMACOLOGY
Twenty years ago an X-ray crystal structure of a bovine throm-
bin complex formed with the peptide-like benzamidine based
inhibitor NAPAP revealed the conformation of an enzyme-bound
thrombin inhibitor and its interactions with the residues of the
active site cleft (Brandstetter et al., 1992). This data spurred
the design of a new class of inhibitor molecules with increased
inhibitory potency toward human α-thrombin and acceptable
metabolic stability and pharmacokinetic properties (Davis and
Teague, 1999; Hauel et al., 2002).
A lead compound (dabigatran; Figure 2A) was identified
because of its favorable selectivity profile and strong in vitro and
in vivo activity, exhibiting long anticoagulation duration in rats
after i.v. administration and toleration at high doses (Wienen et al.,
2007a). However it was not orally active due to its polarity and the
compound was converted into an orally active prodrug (dabiga-
tran etexilate; Himmelsbach et al., 1995). Given orally to rhesus
monkeys, this prodrug exhibited strong and long lasting anticoag-
ulant effects as measured by the activated partial thromboplastin
time (aPTT) ex vivo (Wienen et al., 2007a). Based on its promising
profile, dabigatran etexilate was selected for clinical development.
MOLECULAR MECHANISM OF ACTION OF DABIGATRAN
Dabigatran inhibits human thrombin in a concentration-
dependent and competitive fashion, with a Ki of 4.5 nM. This
inhibition is rapid and reversible, and comparison to IC50 values
for other coagulation proteases demonstrated its high selectiv-
ity for thrombin (Wienen et al., 2007a). Dabigatran inhibits both
clot-bound and free thrombin, and this binding is independent of
whether thrombin is bound via the exosite to fibrin or is present
as free enzyme in plasma (van Ryn et al., 2008).
Thrombin generated on the platelet surface is a potent ago-
nist mediating platelet activation. Dabigatran inhibits thrombin-
induced platelet aggregation, but has no inhibitory effect on
platelet aggregation induced by arachidonic acid, collagen, or
ADP (Wienen et al., 2007a). Dabigatran also effectively inhibits
TF-induced thrombin generation in human platelet poor plasma
(PPP) in a concentration-dependent manner.
IN VITRO ANTIHEMOSTATIC EFFECTS OF DABIGATRAN
Consistent and potent in vitro anticoagulant activity of dabigatran
has been demonstrated using clotting assays across several species
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FIGURE 2 | (A) Surface representation of FIIa bound to dabigatran. The insert
shows a zoom into the active site cleft of the enzyme. The most prominent
feature of the ligand-protein interaction interface is the deep S1 pocket in
which the benzamidine moiety binds. The 60-loop insertion of FIIa with the
prominent Trp-60D occludes a hydrophobic S2 pocket in which the
methylbenzimidazole of dabigatran nicely fits. The S4 pocket is rather shallow
pocket that prefers to bind aromatic moieties of inhibitors. Dabigatran
occupies the S4 pocket with its pyridyl ring that forms an edge-on CH. . .pi
interaction with Trp-215 at the floor of the pocket and places its propionic acid
group into the solvent exposed S3 pocket. (B) Effect of increasing
concentrations of dabigatran on diluted thrombin time measurements in
different species. The EC(T 2) and EC(T 3) represent the effective concentration
of dabigatran to prolong the clotting time either twofold or threefold. Data
represented as mean±SE, n= 4–5.
(Wienen et al., 2007a). A doubling of the aPTT, prothrombin
time (PT), and ecarin clotting time (ECT) is observed at dabi-
gatran concentrations ranging from 0.1 up to 4.6µM, with the
ECT being the most sensitive parameter for anticoagulant activity.
The thrombin time (TT) assay is extremely sensitive to dabiga-
tran’s effects and the commercially available Hemoclot® Thrombin
Inhibitor assay (Hyphen BioMed, Neuville-sur-Oise, France) is a
diluted thrombin time (dTT) assay sensitive enough for accurate
quantitative measurement of dabigatran activity across a broad
concentration range (van Ryn et al., 2010). Thrombin inhibi-
tion by dabigatran was comparable in pig and human plasma,
and inhibition of rat thrombin was ∼20% less potent than
human, and mouse thrombin ∼twofold less potent than human
(Figure 2B).
EX VIVO ANTIHEMOSTATIC EFFECTS OF DABIGATRAN
Significant dose- and time-dependent anticoagulant efficacy ex
vivo has been demonstrated after i.v. administration of dabiga-
tran to rats and rhesus monkeys. In rats, doses of 0.3, 1, and
3 mg/kg i.v. produce a maximum prolongation of the ex vivo aPTT
to 29, 159, and 582 s, respectively, 5 min after administration. In
rhesus monkeys, i.v. administration (0.15, 0.3, or 0.6 mg/kg) of
dabigatran prolongs the aPTT to 47.3, 70.1, and 98.9 s, respec-
tively, 5 min after administration and this is sustained beyond 8 h.
Notably, single oral doses of 1, 2.5, and 5 mg/kg administered to
conscious rhesus monkeys all revealed a significant and long last-
ing (>8 h) prolongation of the aPTT (Hauel et al., 2002; Wienen
et al., 2007a).
VENOUS AND ARTERIAL ANTITHROMBOTIC EFFECTS OF DABIGATRAN
Infusion of dabigatran in a rat model of induced venous throm-
bosis inhibited clot formation dose-dependently and completely
(Wienen et al., 2007b). No significant increase in bleeding time was
observed at the maximum effective antithrombotic dose. In the
same model, dabigatran etexilate administered orally between 0.5
and 7 h prior to thrombus induction resulted in a dose and time-
dependent inhibition of thrombus formation. In a rabbit arterio-
venous shunt model of thrombosis, infusion and oral adminis-
tration of dabigatran revealed a dose-dependent inhibition of clot
formation (Wienen et al., 2007c). In both the rat and rabbit throm-
bosis models the observed antithrombotic effects were inversely
correlated with a dose and time-dependent prolongation of the ex
vivo aPTT.
In the Folts model of arterial thrombosis in pigs, aspirin (ASA)
treatment reduced cyclic flow reductions by 40% and dabigatran
reduced by 44%. Given together, the two compounds reduced clo-
sures by 88% and proved to be safe and effective in this model.
Additionally, a complete closure of the injured vessels was not
observed at clinically relevant plasma levels in the dabigatran-
treated and the dabigatran-ASA treated animals, demonstrating
effectiveness in an arterial thrombosis setting (van Ryn et al., 2009).
PLEIOTROPIC EFFECTS OF THROMBIN – PRECLINICAL
OBSERVATIONS
In addition to its role in hemostasis, thrombin directly and indi-
rectly affects cell behavior and responses in a variety of tissue types
via PAR receptor signaling, and has been implicated in a variety of
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diseases (Coughlin, 2005), suggesting other potential indications
where thrombin inhibition could be beneficial. These therapeutic
areas include diseases underscored by inflammation (van der Poll
et al., 2011), infection (Levi et al., 2012), fibrosis (Chambers and
Laurent, 2002), and cancer (Palumbo and Degen, 2000), among
others. To date, many disease areas where thrombin-PAR signaling
has been implicated are being investigated preclinically for benefi-
cial effects of direct thrombin inhibition by dabigatran and several
are described below. However effects in the clinic are unknown.
ATHEROSCLEROSIS
There is increasing evidence in experimental atherosclerosis that
inflammation and coagulation play an important role in athero-
sclerotic development (Borissoff et al., 2009, 2011). In separate
studies utilizing the Apo E−/− mouse model of atherosclero-
sis, mice were fed high fat control diet or diet supplemented
with dabigatran for up to 20 weeks. In all studies, dabigatran-
fed mice exhibited reduced atherosclerotic lesion size along with
enhanced plaque stability, improved endothelial function, and
reduced oxidative stress (Preusch et al., 2010; Kadoglou et al., 2012;
Lee et al., 2012). Another study in a procoagulant/atherosclerotic
mouse model (ApoE−/−:TMpro/pro) having elevated coagulation
activity due to a loss-of-function mutation in TM demonstrated
that dabigatran significantly reduced plaque area and stenosis after
a carotid cuff injury (Borissoff et al., 2010).
CANCER
A link between cancer and thrombosis has long been recognized
(Iodice et al., 2008) and there is experimental evidence implicat-
ing PAR1-mediated events and expression with tumor growth and
metastasis (Booden et al., 2004). Studies testing the effects of dabi-
gatran treatment (4 weeks) in a syngeneic mouse model of breast
cancer demonstrated a reduction in both primary tumor growth
and metastasis in dabigatran-treated mice as compared to control
(DeFeo et al., 2010).
FIBROSIS
One hallmark of atrial fibrillation and many other degenera-
tive diseases (e.g., renal disease, idiopathic pulmonary fibrosis)
is the extent of fibrosis (Tan and Zimetbaum, 2011). Activation
of coagulation following tissue injury is an early fibrotic response
leading to the deposition of fibrin. Notably, thrombin activation of
PAR1 can differentiate normal lung fibroblasts into a myofibrob-
last phenotype, inducing fibrogenic cytokine release and increased
expression of extracellular matrix proteins (Bogatkevich and Sil-
ver, 2009). These effects are inhibited in vitro by dabigatran, and
in bleomycin-induced pulmonary injury in mice chronic dabiga-
tran etexilate treatment reduced the extent of fibrosis and collagen
release (Bogatkevich et al., 2011).
INFECTIONS WITH STAPHYLOCOCCUS AUREUS
The potential of S. aureus to coagulate blood is used as a diagnostic
feature of the pathogen and more recently it has been shown that S.
aureus achieves this by secreting a procoagulant, called coagulase
(McAdow et al., 2011). Coagulase directly converts prothrom-
bin into thrombin, bypassing upstream coagulation and allows
S. aureus to envelope itself in protective fibrin strands, which may
aid in its resilience to antibiotics (Vanassche et al., 2011). Dabiga-
tran directly inhibits coagulase, unlike heparin and hirudin, and
thus prevents fibrin formation and may increase the sensitivity of
S. aureus to antibiotics (Vanassche et al., 2010, 2011, 2012).
CLINICAL STUDIES AND INDICATIONS
For 50 years VKAs have been the standard in chronic anticoag-
ulation treatment, however their many associated drawbacks has
led to significant clinical underuse in atrial fibrillation patients.
There is a significant unmet medical need to develop anticoagu-
lation treatment that is easy to use, predictable, effective, and safe.
Dabigatran etexilate represents the first broadly approved NOAC
with these attributes.
Dabigatran has a fast onset of action (peak plasma concentra-
tions 2–3 h after ingestion) with a half-life of 12–14 h (Stangier
and Clemens, 2009). It does not require routine coagulation mon-
itoring, has no drug-food interactions, is not metabolized by
cytochrome P 450 enzymes, and does not require dose adjust-
ment for moderate liver disease (Garnock-Jones, 2011). As a
substrate for the Pgp transporter there is the potential for drug
interactions with agents using this transporter (e.g., verapamil,
amiodarone, rifampicin), which may necessitate dose adaptation
(Huisman et al., 2012; Härtter et al., 2012). Dabigatran is 80%
renally excreted, thus prior to commencing dabigatran treatment
renal function should be assessed, and in the instance of emergency
situations dabigatran is dialyzable due to low protein binding
(∼30%; Huisman et al., 2012). As with all anticoagulants, dabi-
gatran’s most common side effect is bleeding. In RE-LY, there was
a significantly higher risk of gastrointestinal bleeding with dabiga-
tran 150 mg bid compared with warfarin (Connolly et al., 2009).
No statistical significant difference was seen when using the 110 mg
BID dabigatran dose. Mild to moderate dyspepsia related to dabi-
gatran was also reported. The side effect tended to be transient,
and may be managed by giving dabigatran with a large glass of
water, with food, or a proton-pump inhibitor (PPI; Bytzer et al.,
2012; Hoffman and Galle, 2013).
PREVENTION OF DEEP VENOUS THROMBOSIS
Dabigatran has been studied in more than 10,000 patients in
four phase III trials of deep venous thrombosis (DVT) and pul-
monary embolism (PE) prophylaxis in major orthopedic surgery
and demonstrated a good overall safety profile in this setting (Fuji
et al., 2010; Dahl et al., 2012; Eriksson et al., 2012a,b). In total
knee replacement (TKR), when compared to enoxaparin 30 mg
twice daily (BID), dabigatran etexilate at 150 and 220 mg once
daily (OAD) was inferior due to a greater number of distal throm-
boses (Ginsberg et al., 2009). In studies comparing dabigatran to
40 mg of enoxaparin, equivalence was shown for both thrombo-
sis prevention and bleeding in total hip replacement (THR) and
TKR (Eriksson et al., 2007a,b). The THR results were reproduced
in the RE-NOVATE II trial and dabigatran additionally demon-
strated superior reduction of major VTE (including DVT and PE)
with a same rate of major bleeding (Eriksson et al., 2011a). A
pooled analysis of the THR trials demonstrated its superiority in
the prevention of major VTE (Friedman et al., 2010; Eriksson et al.,
2011b). In the countries where dabigatran etexilate is approved for
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VTE prophylaxis it is recommended at a dose of 220 or 150 mg
OAD for patients with renal impairment or taking a Pgp inhibitor.
THERAPY OF VENOUS THROMBOEMBOLISM
In the treatment of VTE 150 mg BID dabigatran etexilate was com-
pared to standard warfarin treatment (Schulman et al., 2009).
In the acute treatment setting, all patients received heparin or
LMWH for a median of 9 days prior to treatment with an
oral anticoagulant. Dabigatran demonstrated the same efficacy
in thrombosis prevention with significantly less minor bleeding
and similar major bleeding. The extension studies RE-MEDY
(vs. warfarin) and RE-SONATE (vs. placebo) showed similar
efficacy and improved bleeding profile compared to warfarin,
and a 92% relative risk reduction of recurrent VTE with ele-
vated clinically relevant non-major bleeding but no statistical
difference in major bleeding compared to placebo (Schulman
et al., 2011a,b). The RE-SONATE study showed for the first
time significant efficacy of an oral anticoagulant in the preven-
tion of thromboembolic events with a good safety profile. Acute
treatment and secondary prevention of VTE have not yet been
registered.
STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
In the RE-LY study, 18,113 patients with atrial fibrillation (AF)
and at least one risk factor for stroke were randomized between
warfarin, 110 or 150 mg BID dabigatran etexilate (Connolly et al.,
2009). The RE-LY trial was the only phase III study in the field
of NOACs carrying enough power to evaluate two different doses
and define the most appropriate patient population for a specific
dose. The 150 mg BID dose showed superior efficacy in stroke
prevention and systemic embolism with similar major bleeding
rate compared to well controlled warfarin. The 110 mg BID dose
had a significantly lower major bleeding rate and the same effi-
cacy as warfarin. Both doses showed a significant (up to 70%)
reduction of intracranial hemorrhage and a reduction in life-
threatening bleeding. There was a non-significant 12% mortality
benefit (p= 0.051) with the 150 mg BID dose (Connolly et al.,
2010).
These results were consistent across all patient groups, includ-
ing those with a prior history of stroke or transient ischemic attack
(Diener et al., 2010), patients previously on warfarin, or those
new to oral anticoagulation (Ezekowitz et al., 2010). Interestingly
the effects seen under both doses were independent from gender,
weight, ethnicity, renal impairment grade, CHADS2 scores, con-
comitant diseases (e.g., hypertension, diabetes, heart failure), and
treatments (Connolly et al., 2009, 2010; Eikelboom et al., 2011). A
RE-LY subgroup analysis has indicated an interaction between age
and bleeding endpoints, with dabigatran 150 mg BID efficacy per-
sisting for all age groups while dabigatran 110 mg BID in patients
above 80 years improves safety profile (Eikelboom et al., 2011).
For stroke prevention, the FDA recommends a lower thera-
peutic dose (75 mg BID) in patients with severe renal impairment
[creatinine clearance (CrCl) 15–30 ml/min] and no use in patients
with CrCl under 15 ml/min. In Europe two doses (150, 110 mg
BID) exist which enables tailored dosing and is contraindicated in
patients with a CrCl below 30 ml/min.
PREVENTION OF RECURRENT MYOCARDIAL INFARCTION IN PATIENTS
WITH ACUTE CORONARY SYNDROME
In the RE-DEEM phase II dose identification study, dabigatran
plus dual antiplatelet therapy showed an expected dose-dependent
increase in bleeding and significantly reduced coagulation activity
(Oldgren et al., 2011). In the 150 and 110 mg BID dose groups, the
composite of cardiovascular death, non-fatal myocardial infarc-
tion or hemorrhagic stroke or cardiovascular death or all-cause
death alone were numerically lower compared to placebo (dual
antiplatelet therapy). The safety profile in this post-ACS popu-
lation was acceptable and a RE-LY subanalysis study found that
concomitant use of antiplatelets led to an expected doubling of
bleeding rates in both dabigatran and warfarin treatment groups
(Connolly et al., 2009).
MECHANICAL HEART VALVES
Thromboprophylaxis after mechanical heart valve implantation
is required for the lifetime of the patient, thus the concept of
a DTI as a potential therapy was tested preclinically. In vitro,
human blood anticoagulated with dabigatran circulating over a
mechanical heart valve in a closed circuit effectively prevented
fibrin deposition and thrombus formation compared to control
(Maegdefessel et al., 2010). In an experimental swine model with a
heart valve grafted onto the descending aorta, dabigatran admin-
istered post implantation for 30 days vs. LMWH significantly
reduced valve thrombus and platelet deposition (McKellar et al.,
2011). In a separate study, swine underwent mitral valve replace-
ment and received dabigatran or warfarin for 90 days (Schomburg
et al., 2012). Valve thrombus was observed in all groups; how-
ever there was decreased incidence of bleeding and a significant
mortality benefit in the dabigatran-treated group vs. warfarin.
Dabigatran’s effects in the setting of mechanical valve replace-
ment was investigated in the dose-finding RE-ALIGN phase II
study (Van de Werf et al., 2012), however the study was discon-
tinued because interim analysis showed an increased incidence of
thromboembolic events compared to warfarin. Therefore dabi-
gatran is contraindicated in patients with mechanical prosthetic
valves (FDA Drug Safety Communication, 2012).
SUMMARY
Based on a NAPAP-thrombin X-ray crystal structure a new class
of thrombin inhibitors was designed, with the potency of these
compounds optimized over several iterative steps. One inhibitor,
dabigatran, demonstrated very strong in vivo activity, however due
to its highly polar nature, oral absorption was insufficient. Sev-
eral prodrugs were synthesized from which dabigatran etexilate
emerged as a strong clinical candidate.
Preclinical pharmacological investigations illustrated that dabi-
gatran is an effective antithrombotic agent in both venous and
arterial models. In an unprecedented clinical trial program that
included ∼38,000 patients, dabigatran was shown to be a highly
effective anticoagulant with a good safety profile. Dabigatran is
as effective as enoxaparin in the prevention of venous thrombosis
after orthopedic surgery, and as effective as warfarin in the ther-
apy of acute thrombosis or secondary prevention of VTE with
no increased risk of bleeding. In stroke prevention in atrial fib-
rillation, it was more effective than well controlled warfarin with
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remarkable decreased risk of intracranial hemorrhage. Further-
more, since thrombin has been shown to play a central role in many
disease processes, dabigatran is being investigated in additional
biochemical pathways for potential beneficial effects in preclinical
translational and disease models.
More than 50 years after the introduction of warfarin,
the development of dabigatran can be seen as a break-
through achievement for the treatment of thromboembolic
disease including the prevention of catastrophic strokes in
patients.
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